Bone Marrow TransplantationCyclophosphamideBone MarrowTransplantation, HomologousBone Marrow CellsVidarabineGraft vs Host DiseaseTransplantation, AutologousWhole-Body IrradiationTransplantation ConditioningHematopoietic Stem Cell TransplantationBone and BonesBusulfanAnemia, AplasticTransplantation ChimeraLeukemiaGraft SurvivalLiver TransplantationTissue DonorsAntineoplastic Combined Chemotherapy ProtocolsBone Marrow PurgingHistocompatibility TestingVidarabine PhosphateHistocompatibilityCombined Modality TherapyImmunosuppressive AgentsRemission InductionTreatment OutcomeRecurrenceHematopoietic Stem CellsLeukemia, Lymphocytic, Chronic, B-CellTransplantation, IsogeneicBone Marrow DiseasesLymphoma, Non-HodgkinLeukemia, Myeloid, AcuteHematopoiesisKidney TransplantationHematologic NeoplasmsTime FactorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMice, Inbred C57BLSurvival AnalysisRadiation ChimeraPrecursor Cell Lymphoblastic Leukemia-LymphomaBone Marrow ExaminationGraft RejectionImmunosuppressionLeukemia, MyeloidHepatic Veno-Occlusive DiseaseVincristineStem Cell TransplantationMyelodysplastic SyndromesLymphocyte DepletionDisease-Free SurvivalAcute DiseaseCytarabineGraft vs Host ReactionBone RemodelingSurvival RateTransplantation ImmunologyBone Marrow NeoplasmsEtoposideMelphalanRetrospective StudiesPrednisoneGranulocyte Colony-Stimulating FactorAntineoplastic Agents, AlkylatingHematologic DiseasesT-LymphocytesLeukocyte TransfusionHeart TransplantationFollow-Up StudiesCarmustineHLA AntigensCyclosporineDoxorubicinColony-Forming Units AssayActuarial AnalysisGraft vs Tumor EffectChimeraMethotrexateSevere Combined ImmunodeficiencyLymphocyte TransfusionLeukocyte CountPancytopeniaLung TransplantationMyeloablative AgonistsAntilymphocyte SerumBone DensitySpleenAntibodies, MonoclonalAntineoplastic AgentsMultiple MyelomaInfectionLymphomaDrug Administration ScheduleNuclear FamilyPrognosisMice, Inbred BALB CPeripheral Blood Stem Cell Transplantation